Advertisement
Advertisement

SRPT

SRPT logo

Sarepta Therapeutics,, Inc. Common Stock

17.96
USD
Sponsored
-0.86
-4.57%
Jul 14, 16:00 UTC -4
Closed
exchange

Pre-Market

18.25

+0.29
+1.61%

SRPT Earnings Reports

Positive Surprise Ratio

SRPT beat 19 of 42 last estimates.

45%

Next Report

Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$375.38M
/
$0.23
Implied change from Q1 26 (Revenue/ EPS)
-48.63%
/
-92.01%
Implied change from Q2 25 (Revenue/ EPS)
-38.57%
/
-87.83%

Sarepta Therapeutics,, Inc. Common Stock earnings per share and revenue

On May 06, 2026, SRPT reported earnings of 2.88 USD per share (EPS) for Q1 26, beating the estimate of 1.01 USD, resulting in a 184.67% surprise. Revenue reached 730.80 million, compared to an expected 464.98 million, with a 57.17% difference. The market reacted with a -9.68% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 17 analysts forecast an EPS of 0.23 USD, with revenue projected to reach 375.38 million USD, implying an decrease of -92.01% EPS, and decrease of -48.63% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Lexaria Bioscience Corp. Common Stock
Report Date
Jul 13, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+7.73%
FAQ
For Q1 2026, Sarepta Therapeutics,, Inc. Common Stock reported EPS of $2.88, beating estimates by 184.67%, and revenue of $730.80M, 57.17% above expectations.
The stock price moved down -9.68%, changed from $23.03 before the earnings release to $20.80 the day after.
The next earning report is scheduled for Aug 05, 2026.
Based on 17 analysts, Sarepta Therapeutics,, Inc. Common Stock is expected to report EPS of $0.23 and revenue of $375.38M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement